Kuros Biosciences received approval under the CE Mark for MagnetOs Putty as an osteoconductive, osteoinductive bone void filler inthe spine, extremities, pelvis, cranium, mandible and maxilla.
This follows the company’s earlier CE Mark for granule format, as well as FDA 510(k) clearance for granules and putty as an autograft extender in the posterolateral spine.
Commercial launch is slated later in 2018 for the U.S. and select EU regions.
Kuros Biosciences received approval under the CE Mark for MagnetOs Putty as an osteoconductive, osteoinductive bone void filler inthe spine, extremities, pelvis, cranium, mandible and maxilla.
This follows the company's earlier CE Mark for granule format, as well as FDA 510(k) clearance for granules and putty as an autograft extender in the...
Kuros Biosciences received approval under the CE Mark for MagnetOs Putty as an osteoconductive, osteoinductive bone void filler inthe spine, extremities, pelvis, cranium, mandible and maxilla.
This follows the company’s earlier CE Mark for granule format, as well as FDA 510(k) clearance for granules and putty as an autograft extender in the posterolateral spine.
Commercial launch is slated later in 2018 for the U.S. and select EU regions.
Copy to clipboard 
